WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011149824) CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/149824    International Application No.:    PCT/US2011/037529
Publication Date: 01.12.2011 International Filing Date: 23.05.2011
IPC:
A61K 31/4196 (2006.01), A61K 31/7004 (2006.01), A61K 31/404 (2006.01), A61K 31/423 (2006.01), A61K 45/06 (2006.01), A61P 35/00 (2006.01)
Applicants: SYNTA PHARMACEUTICALS CORP. [US/US]; 45 Hartwell Avenue Lexington, MA 02421 (US) (For All Designated States Except US).
BLACKMAN, Ronald, K. [US/US]; (US) (For US Only).
FOLEY, Kevin, Paul [US/US]; (US) (For US Only).
PROIA, David [US/US]; (US) (For US Only)
Inventors: BLACKMAN, Ronald, K.; (US).
FOLEY, Kevin, Paul; (US).
PROIA, David; (US)
Agent: DAVIS, Steven, G.; McCarter & English, LLP 265 Franklin Street Boston, MA 02110 (US)
Priority Data:
61/347,685 24.05.2010 US
Title (EN) CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR
(FR) TRAITEMENT ANTICANCÉREUX UTILISANT UNE COMBINAISON D'UN COMPOSÉ INHIBITEUR DE HSP90 ET D'UN INHIBITEUR DE LA TOPOISOMÉRASE II
Abstract: front page image
(EN)A pharmaceutical combination comprising a topoisomerase II inhibitor, and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
(FR)L'invention concerne une combinaison pharmaceutique comprenant un inhibiteur de la topoisomérase II et un inhibiteur de Hsp90 représentés par les formules suivantes, un tautomère ou un sel pharmaceutiquement acceptable de celui-ci, les variables dans les formules structurales étant définies dans le descriptif. L'invention concerne aussi une méthode de traitement d'un trouble prolifératif chez un sujet nécessitant un tel traitement, au moyen de la combinaison pharmaceutique décrite.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)